Action Potential Venture Capital
Status
ACTIVE
Global HQ
Scotts Valley, USA
Countries of investment
- USA
- Canada
Investment stages
- Seed
- Series A
- Series B
Industries
- Health Tech
- Biotech
- Pharmaceuticals
- Medical Devices
- Digital Health
About
Action Potential Venture Capital (APVC) is a leading medical technology venture capital firm founded by GSK in 2013. APVC invests globally and takes a handson role on the boards of startups advancing bioelectronic medicines and their enabling technologies. The firm is committed to fostering an inclusive and diverse workspace, contributing to a more equitable healthcare investor and entrepreneurial community. APVC's investment team expressly extends this commitment to the companies They invest in. APVC backs teams developing innovative medical and health tech solutions, focusing on transformative therapies and technologies aimed at improving patient outcomes.
Action Potential Venture Capital (APVC) is a leading medical technology venture capital firm founded by GSK in 2013. APVC invests globally and takes a handson role on the boards of startups advancing bioelectronic medicines and their enabling technologies. The firm is committed to fostering an inclusive and diverse workspace, contributing to a more equitable healthcare investor and entrepreneurial community. APVC's investment team expressly extends this commitment to the companies They invest in. APVC backs teams developing innovative medical and health tech solutions, focusing on transformative therapies and technologies aimed at improving patient outcomes.
Investment Thesis
APVC is dedicated to bringing bioelectronic medicines to patients by supporting innovators and entrepreneurs pioneering a bioelectronic future.
Team
Robert E. Glass
Partner
Brian Otis
Partner
Karl Johnson
Principal
Portfolio
Neuspera Medical
Cala
Exo
Alpheus Medical
Cala Health
CVRx
Exo Imaging
MicroTransponder
Neuspera
Onc AI
Presidio Medical
Saluda Medical
SetPoint Medical
Onc.ai
Allay Therapeutics
Avation Medical
Francis Medical
Health Scholars
Koya Medical
RareCyte